Antiviral drug discovery: preparing for the next pandemic.
Antiviral Agents
/ chemistry
Biological Products
/ chemistry
COVID-19
/ prevention & control
Coronavirus Protease Inhibitors
/ chemistry
Drug Discovery
/ methods
Humans
Molecular Docking Simulation
Molecular Targeted Therapy
/ methods
Nucleic Acid Synthesis Inhibitors
/ chemistry
Pandemics
/ prevention & control
RNA, Viral
/ antagonists & inhibitors
SARS-CoV-2
/ chemistry
Small Molecule Libraries
/ chemistry
COVID-19 Drug Treatment
Journal
Chemical Society reviews
ISSN: 1460-4744
Titre abrégé: Chem Soc Rev
Pays: England
ID NLM: 0335405
Informations de publication
Date de publication:
21 Mar 2021
21 Mar 2021
Historique:
pubmed:
2
2
2021
medline:
13
4
2021
entrez:
1
2
2021
Statut:
ppublish
Résumé
Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts.
Substances chimiques
Antiviral Agents
0
Biological Products
0
Coronavirus Protease Inhibitors
0
Nucleic Acid Synthesis Inhibitors
0
RNA, Viral
0
Small Molecule Libraries
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3647-3655Subventions
Organisme : Medical Research Council
ID : MR/V028464/1
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn